MiMedx Group (MDXG) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

MiMedx Group (MDXG) overview

MiMedx Group (MDXG) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 419m and operating profit of USD 63.9m; the year-end share price was 6.77 USD and market capitalisation was USD 1,003m. MiMedx Group is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get MiMedx Group's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 257mFY 2025
Share price6.77 USDFY 2025 year end
RevenueUSD 419mFY 2025
Operating profitUSD 63.9mFY 2025
Net earningsUSD 48.6mFY 2025
Market capitalisationUSD 1,003mFY 2025 year end

About MiMedx Group

MiMedx Group provides products for wound care, burn treatment, and surgical applications. Its portfolio includes human placental allografts, an animal-derived collagen matrix, and distributed wound-care products such as platelet-rich plasma gel, bioglass and collagen dressings, and peptide matrix. Clinicians use its products to help treat chronic and hard-to-heal wounds and support healing in surgical specialties.

Generate the MiMedx Group report

MiMedx Group is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for MiMedx Group and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on MiMedx Group

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.